These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer. Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339 [TBL] [Abstract][Full Text] [Related]
4. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells. Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267 [TBL] [Abstract][Full Text] [Related]
5. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019 [TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database. Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448 [TBL] [Abstract][Full Text] [Related]
7. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes. Liu Z; Deng M; Wu L; Zhang S Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476 [TBL] [Abstract][Full Text] [Related]
8. A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer. Lin SH; Zhang J; Giri U; Stephan C; Sobieski M; Zhong L; Mason KA; Molkentine J; Thames HD; Yoo SS; Heymach JV J Thorac Oncol; 2014 Jul; 9(7):965-973. PubMed ID: 24922006 [TBL] [Abstract][Full Text] [Related]
10. Clinical and Pathological Characteristics of Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460 [No Abstract] [Full Text] [Related]
11. Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas. Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y Mol Med Rep; 2012 Aug; 6(2):391-4. PubMed ID: 22614957 [TBL] [Abstract][Full Text] [Related]
12. Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines. Schilling D; Bayer C; Emmerich K; Molls M; Vaupel P; Huber RM; Multhoff G Strahlenther Onkol; 2012 Apr; 188(4):353-8. PubMed ID: 22318330 [TBL] [Abstract][Full Text] [Related]
13. NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells. Guan L; Nambiar DK; Cao H; Viswanathan V; Kwok S; Hui AB; Hou Y; Hildebrand R; von Eyben R; Holmes BJ; Zhao J; Kong CS; Wamsley N; Zhang W; Major MB; Seol SW; Sunwoo JB; Hayes DN; Diehn M; Le QT Cancer Res; 2023 Mar; 83(6):861-874. PubMed ID: 36652552 [TBL] [Abstract][Full Text] [Related]
14. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347 [TBL] [Abstract][Full Text] [Related]
15. Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report. Nishimura R; Yoshida T; Torasawa M; Kashihara T; Ohe Y Thorac Cancer; 2023 Jan; 14(2):206-209. PubMed ID: 36453575 [TBL] [Abstract][Full Text] [Related]
16. Multiomics Differences in Lung Squamous Cell Carcinoma Patients with High Radiosensitivity Index Compared with Those with Low Radiosensitivity Index. Du Y; Yuan S; Zhuang X; Zhang Q; Qiao T Dis Markers; 2021; 2021():3766659. PubMed ID: 34504628 [TBL] [Abstract][Full Text] [Related]
17. Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404 [TBL] [Abstract][Full Text] [Related]
18. Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks. Michna A; Schötz U; Selmansberger M; Zitzelsberger H; Lauber K; Unger K; Hess J Radiat Oncol; 2016 Jul; 11():94. PubMed ID: 27455841 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. Bonelli MA; Cavazzoni A; Saccani F; Alfieri RR; Quaini F; La Monica S; Galetti M; Cretella D; Caffarra C; Madeddu D; Frati C; Lagrasta CA; Falco A; Rossetti P; Fumarola C; Tiseo M; Petronini PG; Ardizzoni A Mol Cancer Ther; 2015 Aug; 14(8):1916-27. PubMed ID: 26013318 [TBL] [Abstract][Full Text] [Related]
20. Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]